Bogle Investment Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Bogle Investment Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-41,982	Closed	-$707K	–	354
2018 Q2	$707K	Sell	41,982 -287	-0.7%	-$5.57K	0.05%	229
2018 Q1	$968K	Sell	42,269 -249,741	-86%	-$5.55M	0.07%	227
2017 Q4	$7.55M	Buy	+292,010	New	+$5.88M	0.55%	77
2016 Q3	–	Sell	-11,909	Closed	-$133K	–	469
2016 Q2	$133K	Sell	11,909 -8,691	-42%	-$111K	0.01%	370
2016 Q1	$281K	Sell	20,600 -128,235	-86%	-$1.85M	0.02%	355
2015 Q4	$2.82M	Sell	148,835 -87,682	-37%	-$1.91M	0.2%	145
2015 Q3	$4.44M	Buy	+236,517	New	+$4.02M	0.32%	116
2015 Q1	–	Sell	-113,894	Closed	-$1.52M	–	436
2014 Q4	$1.52M	Buy	+113,894	New	+$1.47M	0.1%	224

Other funds holding CNCE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bogle Investment Management's CNCE Position: Q3 2018 in Review

Bogle Investment Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2018, closing a stake of 41,982 shares — an estimated $707K sold.

Bogle Investment Management first reported a position in CNCE in Q4 2014 and held it in 8 quarters. The position peaked at $7.55M in Q4 2017. 111 funds tracked by Wall St. Rank hold CNCE as of Q3 2018.

Bogle Investment Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Bogle Investment Management sold 41,982 Concert Pharmaceuticals, Inc. shares in Q3 2018, an estimated $707K.
Bogle Investment Management first reported a position in Concert Pharmaceuticals, Inc. in Q4 2014 and held it in 8 quarters.
Bogle Investment Management's Concert Pharmaceuticals, Inc. position peaked at $7.55M in Q4 2017.
111 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2018.

Based on Bogle Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.